Adrian Hepner
Nessuna posizione attualmente
Profilo
Adrian J.
Hepner served as Senior Medical Director at UCB Biosciences, Inc. from 2012 to 2013, Vice President-Clinical Research at Avanir Pharmaceuticals, Inc. from 2006 to 2012, VP-Clinical Research & Medical Affairs at BioDelivery Sciences International, Inc. from 2013 to 2014, Chief Medical Officer & Executive Vice President at Eagle Pharmaceuticals, Inc. from 2016 to 2020, Chief Medical Officer at Pharnext SA from 2020 to 2022, and currently serves as President & Chief Medical Officer at Coya Therapeutics, Inc. Hepner received his graduate and doctorate degrees from Universidad de Buenos Aires in 1986 and 1983, respectively.
Precedenti posizioni note di Adrian Hepner
Società | Posizione | Fine |
---|---|---|
COYA THERAPEUTICS, INC. | President | 17/07/2023 |
PHARNEXT SCA | Chief Tech/Sci/R&D Officer | 01/01/2022 |
EAGLE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/07/2020 |
BIODELIVERY SCIENCES INTERNATIONAL, INC. | Chief Tech/Sci/R&D Officer | 01/12/2014 |
UCB BioSciences, Inc. | Corporate Officer/Principal | 01/01/2013 |
Formazione di Adrian Hepner
Universidad de Buenos Aires | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
EAGLE PHARMACEUTICALS, INC. | Health Technology |
PHARNEXT SCA | Health Technology |
COYA THERAPEUTICS, INC. | Health Technology |
Aziende private | 3 |
---|---|
Avanir Pharmaceuticals, Inc.
Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
BioDelivery Sciences International, Inc.
BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
UCB BioSciences, Inc. |
- Borsa valori
- Insiders
- Adrian Hepner